A. Rowland

Humanization of an anti-p185HER2 antibody for human cancer therapy.

L. Presta, P. Carter, C. Gorman, 1992, Proceedings of the National Academy of Sciences of the United States of America.

High Level Escherichia coli Expression and Production of a Bivalent Humanized Antibody Fragment

Brad Snedecor, B. Snedecor, P. Carter, 1992, Bio/Technology.

Ligand-mediated immunofunctional assay for quantitation of growth hormone-binding protein in human blood.

A. Rowland, R. Clark, L. Carlsson, 1991, The Journal of clinical endocrinology and metabolism.

A simple approach to improving sensitivity in a one-step monoclonal antibody-based ELISA for human IIbIIIa using multiple conjugates.

A. Rowland, W. L. Wong, M. Wooldridge, 1992, Journal of immunological methods.

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome

Justin J. W. Powell, E. Kavanagh, D. Brough, 2022, Neuropharmacology.

Expression of vascular endothelial growth factor does not promote transformation but confers a growth advantage in vivo to Chinese hamster ovary cells.

J. Winer, H. Phillips, A. Rowland, 1993, The Journal of clinical investigation.

Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms.

J. Winer, A. Rowland, N. Ferrara, 1992, The Journal of biological chemistry.

Expression and secretion of gro/MGSA by stimulated human endothelial cells.

R. Derynck, A. Rowland, D. Wen, 1989, The EMBO journal.

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome

Justin J. W. Powell, E. Kavanagh, D. Brough, 2022, Neuropharmacology.